Zobrazeno 1 - 10
of 5 501
pro vyhledávání: '"Gip"'
Autor:
Engin Yurtcu, Betul Keyif, Gamze Yilmaz, Selcuk Erkilinc, Hatice Akkaya, A. Seval Ozgu-Erdinc
Publikováno v:
Diabetology & Metabolic Syndrome, Vol 16, Iss 1, Pp 1-10 (2024)
Abstract Background This study aimed to evaluate the role of serum Glucagon-Like Peptide-1 (GLP-1), Glucagon-Like Peptide-2 (GLP-2), and Glucose-Dependent Insulinotropic Polypeptide (GIP) levels in relation to obesity and gestational diabetes mellitu
Externí odkaz:
https://doaj.org/article/678903140fd74c868b3f751d3fd77a01
Autor:
Signe Tellerup Nielsen, Belinda Kweka, George Praygod, Suzanne Filteau, Mette Frahm Olsen, Henrik Friis, Daniel Faurholt-Jepsen, Rikke Krogh-Madsen
Publikováno v:
Clinical Diabetes and Endocrinology, Vol 10, Iss 1, Pp 1-5 (2024)
Abstract Aim Type 2 diabetes is increasing in Sub-Saharan Africa, but the pathophysiology in this population is poorly investigated. In Western populations, the incretin effect is reduced in type 2 diabetes, leading to lowered insulin secretion. The
Externí odkaz:
https://doaj.org/article/89901c016acc40638c1a9b0f63b8fa49
Autor:
Fatemeh Taktaz, Rosaria Anna Fontanella, Lucia Scisciola, Ada Pesapane, Manuela Giovanna Basilicata, Puja Ghosh, Martina Franzese, Giovanni Tortorella, Armando Puocci, Maria Teresa Vietri, Annalisa Capuano, Giuseppe Paolisso, Michelangela Barbieri
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-13 (2024)
Abstract Tirzepatide is a new drug targeting glucagon-like peptide 1(GLP1) and gastric inhibitory polypeptide (GIP) receptors. This drug has demonstrated great potential in improving the clinical outcomes of patients with type 2 diabetes. It can lead
Externí odkaz:
https://doaj.org/article/4ca156c215ba43d686dcdf0858b6834f
Publikováno v:
Journal of Education, Health and Sport, Vol 71 (2024)
INTRODUCTION AND PURPOSE. While obesity and type 2 diabetes mellitus (T2DM) are defined (according to WHO) as civilization diseases we are still searching for the ideal tool to fight them. Recently, the Food and Drug Administration (FDA) and European
Externí odkaz:
https://doaj.org/article/f91ddd15c75345829593d745d468904e
Autor:
Katsunori Nonogaki
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/4feba8dcd7dd4a2895afe896cb11ad64
Publikováno v:
Molecular Metabolism, Vol 89, Iss , Pp 102027- (2024)
Objectives: The potential benefits of combining lifestyle changes with weight loss pharmacotherapies for obesity treatment are underexplored. Building on recent clinical observations, this study aimed to determine whether “lead-in” calorie restri
Externí odkaz:
https://doaj.org/article/981023acabc740eea5c5acc57d2c9cae
Autor:
Tayla A. Rees, Benjamin J. Buttle, Zoe Tasma, Sung-Hyun Yang, Paul W. R. Harris, Christopher S. Walker
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Type 2 diabetes (T2D) and obesity are prevalent metabolic disorders affecting millions of individuals worldwide. A new effective therapeutic drug called tirzepatide for the treatment of obesity and T2D is a dual agonist of the GIP receptor and GLP-1
Externí odkaz:
https://doaj.org/article/0907ffccbaea49f58081214071b5e048
Autor:
Mette H. Jensen, Samra J. Sanni, Ditte Riber, Jens J. Holst, Mette M. Rosenkilde, Alexander H. Sparre-Ulrich
Publikováno v:
Molecular Metabolism, Vol 88, Iss , Pp 102006- (2024)
Objectives: Obesity represents a global health crisis with significant patient burdens and healthcare costs. Despite the advances with glucagon-like peptide-1 (GLP-1) receptor agonists in treating obesity, unmet needs remain. This study characterizes
Externí odkaz:
https://doaj.org/article/25f7b2dd9c3443ce984912d0de8ad0d3
Autor:
Chrysoula Boutari, Konstantinos Stefanakis, Stamatia Simati, Valentina Guatibonza-García, Laura Valenzuela-Vallejo, Ioanna A. Anastasiou, Margery A. Connelly, Alexander Kokkinos, Christos S. Mantzoros
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-15 (2024)
Abstract Background Growth differentiation factor 15 (GDF15) is a mitokine, the role of which, total or H-specific, in modulating energy metabolism and homeostasis in obesity-related diseases, such as metabolic dysfunction associated steatotic liver
Externí odkaz:
https://doaj.org/article/0a8f937a73294498bb059c4858f89f9a
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.